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Abstract
Interstitial fibrosis and tubular atrophy (IF/TA) are the most common cause of renal graft failure. Chronic transplant glomerulopathy 
(CTG) is present in approximately 1.5-3.0% of all renal grafts. We retrospectively studied the contribution of CTG and recurrent 
post-transplant glomerulopathies (RGN) to graft loss. We analyzed 123 patients with chronic renal allograft dysfunction and divided 
them into three groups: CTG (N = 37), RGN (N = 21), and IF/TA (N = 65). Demographic data were analyzed and the variables 
related to graft function identified by statistical methods. CTG had a significantly lower allograft survival than IF/TA. In a multivari-
ate analysis, protective factors for allograft outcomes were: use of angiotensin-converting enzyme inhibitor (ACEI; hazard ratio 
(HR) = 0.12, P = 0.001), mycophenolate mofetil (MMF; HR = 0.17, P = 0.026), hepatitis C virus (HR = 7.29, P = 0.003), delayed 
graft function (HR = 5.32, P = 0.016), serum creatinine ≥1.5 mg/dL at the 1st year post-transplant (HR = 0.20, P = 0.011), and 
proteinuria ≥0.5 g/24 h at the 1st year post-transplant (HR = 0.14, P = 0.004). The presence of glomerular damage is a risk factor 
for allograft loss (HR = 4.55, P = 0.015). The presence of some degree of chronic glomerular damage in addition to the diagnosis 
of IF/TA was the most important risk factor associated with allograft loss since it could indicate chronic active antibody-mediated 
rejection. ACEI and MMF were associated with better outcomes, indicating that they might improve graft survival.
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The terminology “interstitial fibrosis and tubular atrophy 
(IF/TA) with no evidence of any specific etiology” recently 
replaced “chronic allograft nephropathy”, and is used to 
describe biopsies with fibrosis and atrophy and with no obvi-
ous underlying pathogenesis (1). IF/TA is the most common 
cause of late renal graft failure (1,2). Several pathophysi-
ological processes contribute to it, such as chronic alloim-
mune injury, drug nephrotoxicity, chronic hypertension, with 
chronic obstruction and post-transplant glomerulopathy 
being the most distinctive ones (2). 
The incidence of chronic transplant glomerulopathy 
(CTG) is about 1.5-3% of all renal grafts (3-5). According 
to Banff 09 criteria (6), CTG, called in this classification 
“chronic active antibody-mediated rejection” is character-
ized by C4d positive staining, the presence of circulating 
antidonor antibodies, morphologic evidence of chronic 
tissue injury, such as glomerular double contours and/or 
peritubular capillary basement membrane multilayering and/
or interstitial fibrosis/tubular atrophy and/or fibrous intimal 
thickening in arteries.
The pathogenesis of CTG is not clear (3). It has been 
associated with circulating anti-donor human leukocyte 
antigen (HLA) antibodies and the deposition of the comple-
ment split product C4d in the peritubular capillaries sug-
gesting antibody-mediated injury (7-9). It has also been 
suggested that the same immune process that causes 
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the intimal proliferation characteristic of chronic vascular 
involvement (humoral immunity) in arteries and arterioles 
is expressed in the glomeruli as chronic transplant glom-
erulopathy. Several aspects of solid organ transplants were 
discussed at the 10th Banff Conference (6), with special 
emphasis on antibody-mediated graft injury, and six Banff 
working groups were formed, one of which will evaluate 
glomerular lesion scoring. 
Recurrence of glomerular disease after transplantation 
is the third most important cause of graft loss after one year 
(10). The prevalence is variable (6.0 to 19.4%) and can 
increase with time after transplant (10). 
Even though histological and laboratory parameters 
can distinguish CTG from recurrent post-transplant glom-
erulonephritis (RGN), an early diagnostic assessment may 
be difficult in certain types of glomerular diseases such as 
membranoproliferative glomerulonephritis, and in some 
cases of IgA nephropathy and focal segmental glomerulo-
sclerosis (FSGS) (11). Moreover, there are still controversies 
concerning the diagnosis, the best treatment option and the 
prognostic factors related to these conditions in the context 
of renal allograft survival. 
We hypothesize that glomerular involvement in a fibrotic 
graft might represent an additional negative prognostic factor 
and ultimately could further reduce graft survival. It is known 
that in kidney transplantation, chronic allograft nephropa-
thy might be followed or not by glomerular involvement. 
Furthermore, patients might present other diseases with 
pronounced glomerular involvement, among them recurrent 
glomerulonephritis and transplant glomerulopathy. These 
are different physiopathogenic conditions and their impact 
on graft survival has not been fully addressed. Therefore, 
we compared groups with glomerular involvement to pa-
tients with IF/TA without glomerular involvement, since all 
patients have some degree of renal fibrosis.
Patients and Methods
Study population
All 1990 biopsies of deceased and living related kidney 
transplant patients performed at the Federal University of 
São Paulo between 2000 and 2003, with at least 6 months 
of graft function, were retrospectively reviewed. A total of 
450 biopsy-proven diagnoses of IF/TA were initially identi-
fied. Biopsies were not included in the study if the patients: 
1) were recipients of a previous organ transplant, 2) were 
recipients of a multi-organ transplant; 3) had a high im-
munological risk at the time of transplantation, defined 
as having a previously measured panel-reactive antibody 
grade >60%, 4) did not have a second later biopsy to be 
re-examined, 5) had a current or previous polyoma virus 
infection and/or tumors, 6) had a de novo post-transplant 
glomerulonephritis or an RGN with an unknown primary 
etiology of chronic renal disease, and 7) had hemolytic 
uremic syndrome and microangiopathic abnormalities. 
Inclusion criteria were: 1) patients with biopsy-proven IF/
TA and 2) with available clinical and laboratory data in their 
medical records. 
Finally, we selected 123 patients who were divided into 
three groups: group 1 was the CTG group (N = 37) and group 
2 was the RGN group (N = 21), including only IgA nephropathy 
(N = 7), membranoproliferative glomerulonephritis (N = 9), 
and diffuse proliferative glomerulonephritis (corresponding 
to the predominance of proliferation of endocapillary cells in 
the renal biopsy, N = 5). Since chronic transplant glomerul-
opathy could present histologically as glomerular sclerosis, 
we decided to exclude the cases of recurrent, classical, 
nephrotic-associated FSGS from the present analysis due to 
the fact that it is usually easy to establish the clinical diagnosis 
of recurrent FSGS. Membranous glomerulonephritis was 
excluded because we had two cases and the recurrence of 
the disease was late along the post-transplantation course 
(45 and 120 months). For group 3 (N = 65), we selected all 
biopsies with IF/TA without any grade of glomerular damage. 
We then randomized the sample and selected a number of 
cases that was almost double those with CTG to compose 
this group. 
Operational definitions
Delayed graft function was defined as the requirement 
of dialysis during the first week after transplantation without 
rejection and/or technical problems. Early rejection was 
defined when patients with graft dysfunction presented a 
biopsy that matched Banff 05 criteria or when the dysfunction 
resolved after a minimum of 3 doses of methylprednisolone 
over three days, in the absence of other causes of dysfunc-
tion. Any rejection before the 3rd month of transplantation 
was classified as early rejection and, after this period, as late 
rejection. Systemic arterial hypertension was defined as a 
repeated elevated blood pressure exceeding 140 x 90 mmHg 
or when patients were using at least one antihypertensive 
drug. New onset of diabetes after transplantation was defined 
when fasting plasma glucose was ≥126 mg/dL (≥7 mM), 
when a random blood sugar level ≥200 mg/dL (≥11.1 mM) 
was detected, accompanied by symptoms, or an oral glucose 
tolerance test value ≥200 mg/dL (12). Renal function was 
measured by serum creatinine and by creatinine clearance 
calculated with the Cockcroft-Gault equation. 
Outcomes
Graft loss was defined as permanent return to dialysis 
or estimated glomerular filtration rate <15 mL·min-1·1.73 
(m2)-1. For the calculation of functional graft survival, 
patients who died with a functioning graft were eliminated 
from the study. 
Histological analyses
Biopsy specimens of all cases were evaluated and 
graded according to the Banff 05 criteria (12). IF/TA was 
divided into three grades according to the Banff 05 clas-
Kidney graft outcome and post-transplant glomerular diseases 559
www.bjournal.com.br Braz J Med Biol Res 43(6) 2010
sification, which evaluates the severity of IF/TA: grade I 
corresponding to mild IF and TA (<25% of cortical area), 
grade II corresponding to moderate IF and TA (26-50% of 
cortical area), and grade III corresponding to severe IF 
and TA (>50% of cortical area; may include non-specific 
vascular and glomerular sclerosis, but severity is graded 
by tubulointerstitial features). At least four stained slides 
were used to quantify histological changes in each biopsy, 
one stained with hematoxylin-eosin, one with Masson’s 
trichrome, one with periodic acid-Schiff, and one with 
silver. All biopsy specimens were also reviewed by two 
independent observers (pathologists) before inclusion in 
the study. The severity of acute and chronic lesions in each 
renal compartment was calculated by applying concordance 
criteria among these observers. The kappa index was used 
to assess inter-rater reliability when observing or otherwise 
coding qualitative/categorical variable (kappa >0.70 is 
considered to be satisfactory).
The kappa index was 0.85 (95%CI = 0.75-0.95), and 
observed agreement 0.90. When there was a discrepancy 
between the two pathologists, the mean values for each 
variable was used as the final grade of lesion severity. 
Criteria for the definition of chronic transplant  
glomerulopathy
The criteria were: light microscopy showing double 
contours of the glomerular basement membrane in at 
least 10% of the most severely affected tuft, 2) negative 
immunofluorescence or few deposits of IgM and/or C3, 3) 
electron microscopy revealing reduplication of the glomeru-
lar basement membrane and subendothelial accumulation 
of electron-lucent material, 4) C4d positive staining, and 5) 
presence of circulating antidonor antibodies (not available 
in 90% of the patients).
Immunofluorescence analysis was available for 71% of 
the RGN cases, 60% of the CTG cases, and 30% of the IF/
TA cases. C4d positive staining and electron microscopy 
were not routinely performed (only when indicated by the 
assistant physician), being available for 50% (31% from IF/
TA patients, 71% from RGN patients, and 73% from CTG 
patients), and 52% (31% from IF/TA patients, 76% from 
RGN patients, and 78% from CTG patients) of all renal 
biopsies, respectively.
The Banff 05 and Banff 07 classifications were used for 
the diagnosis of IF/TA and CTG, respectively. Light micros-
copy and immunofluorescence were used for RGN cases. 
Electron microscopy was used only in cases in which light 
and immunofluorescence microscopy techniques were not 
able to clarify the diagnoses. 
Statistical analysis
Ages of donors and recipients were considered to be 
continuous and categorical variables (donor’s age above or 
below 39 years, recipient’s age above or below 34 years) 
based on the median donors’ and recipient’ ages. The pres-
ence of proteinuria was recorded as a numerical variable in 
grams per day (24-h urine collections). In further analysis, 
proteinuria was categorized into ≥1 and ≥0.5 g/24 h. Chi-
square and Fisher exact tests were performed to compare 
demographic covariates between groups when appropriate. 
Data are reported as means ± SD. The Student t-test and 
ANOVA were used to compare the mean values among 
groups, with the level of significance set at P < 0.05 (two-
tailed). The Kaplan-Meier method was used to estimate 
graft survival, not including the death of patients with a 
functioning graft. Statistical significance was determined by 
log-rank comparisons of survival curves using two-sided P 
values. Data are reported as means ± SD and, when ap-
propriate, as median and ranges. A multivariate model, the 
Cox proportional hazards model, was used to analyze the 
relationship between graft loss and the other covariates, 
including those that were significant in univariate analysis 
or the variables that we considered clinically relevant. The 
Cox proportional hazard model (backward step) was used to 
obtain the final model of significant predictors and confound-
ing variables were analyzed when required. There was no 
confusion when the exponential coefficient (hazard ratio, 
HR) did not change more than 10%. The Stata statistical 
software (SPSS) 12.0 was used for all statistical analyses 
(Stata Corporation, USA). 
Results
Demographic analysis of the enrolled population
The groups were matched according to gender (58% 
males), recipient age (34 ± 13 years) and transplantation 
time. The immunosuppressive treatment (intention to treat) 
corresponded to cyclosporine A, prednisone and azathio-
prine for 80% of the patients. All patients were treated with 
prednisone (data not shown). The mean period of follow-
up after transplantation was 50 ± 29 months (range 6-140 
months). During this period, 24 grafts were lost at 51 ± 32 
months (range 6-115 months) due to noncompliance with 
treatment (N = 1), acute rejection (N = 3), IF/TA (N = 10), and 
chronic antibody-mediated rejection (N = 10). The groups 
differed in mean period of time from transplantation to graft 
biopsy. Even though serum creatinine levels did not differ 
among groups at the time of the biopsy, the CTG group had 
higher serum creatinine levels (2.3 ± 1.7 mg/dL) compared 
to the RGN (1.6 ± 0.5 mg/dL) and IF/TA groups (1.9 ± 0.6 
mg/dL). Twenty-four-hour proteinuria differed significantly 
between the CTG (1.8 ± 1.8 g/24 h) and IF/TA (0.2 ± 0.5 
g/24 h) groups, as well as between the IF/TA and RGN (2.1 
± 2.2 g/24 h) groups. 
The presence of glomerulitis in the different groups was 
as follows: CTG (N = 1) = 30%; RGN (N = 6) = 29%; IF/TA 
0% (P = 0.000), and the presence of hyalinosis was: CTG 
= 73%, RGN = 48%, IF/TA = 31% (P = 0.000).
Univariate analysis showed that dialysis time, age and 
gender of donor, type of donor, age of recipient, positive 
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hepatitis B virus and hepatitis C virus (HCV) serology, post-
transplant diabetes mellitus, time of ischemia, delayed graft 
function, and type and number of acute rejection episodes 
were not significantly different among groups. In contrast, 
the number of antihypertensive drugs, proteinuria ≥0.5 g/24 
h at 1st year post-transplantation, cytomegalovirus (CMV) 
antigenemia, the use of angiotensin converting enzyme 
inhibitor (ACEI), the use of mycophenolate mofetil (MMF), 
and the degree of HLA matching with a living donor differed 
significantly among groups (see Table 1). 
There was a difference in mean period of time from 
transplantation to graft biopsy among groups. The grade of 
IF/TA by Banff 05 (≥ grade II) was significantly different (P 
= 0.000) among CTG (N = 29, 78%), RGN (N = 14, 23%) 
and IF/TA (N = 17, 28%) patients.
Allograft survival and multivariate analysis
Graft survival is shown in Figures 1 and 2 according to 
time of transplantation and time between biopsy and last 
follow-up. Patients in the CTG and RGN groups had a faster 
progression of allograft dysfunction and a lower allograft 
survival than those in the IF/TA group (P = 0.013) after the 
diagnosis of the morphologic lesion. Allograft survival at 
the 2-year post-diagnostic biopsy was 75% for CTG, 58% 
for RGN and 85% for IF/TA. On the other hand, allograft 
survival at the 1st, 5th and 7th year post-transplant was 
statistically different among groups (P = 0.004), with the 
following respective values: CTG = 97, 80 and 67%; RGN 
= 90, 67 and 14%; IF/TA = 100, 84 and 80%. 
Multivariate analysis using the Cox model revealed the 
following predictive factors for allograft outcome: use of 
ACEI (HR = 0.12, 95%CI = 0.03-0.41, P < 0.001), use of 
MMF (HR = 0.17, 95%CI = 0.03-0.80, P = 0.026), serum 
creatinine ≤1.5 mg/dL by the 1st year post-transplant (HR = 
0.20, 95%CI = 0.05-0.69, P < 0.001), and proteinuria ≤0.5 
g/24 h by the 1st year post-transplant (HR = 0.14, 95%CI = 
Table 1. Demographic, laboratory, clinical, and histological characteristics of the patients. 
CTG (N = 37) RGN (N = 21) IF/TA (N = 65) P+ P*
Recipient age (years) 38 ± 12 35 ± 13 32 ± 13 ns nsª, 0.042b
Donor age (years) 39 ± 9 33 ± 12 38 ± 15 ns nsª, nsb
Number of antihypertensive drugs in use 2 ± 0.85 1.43 ± 0.9 1.58 ± 0.8 0.020 0.043ª, nsb
Proteinuria (g/24 h) at 1st year post-Tx 1.0 ± 2.1 1.7 ± 3.8 0.2 ± 0.9 0.020 nsª, nsb
Total acute rejection episodes 0.5 ± 0.61 0.25 ± 0.5 0.54 ± 0.7 ns 0.182ª, 0.996b
Early rejection episodes <3 months (N, %) 14 (38%) 5 (24%) 29 (45%) ns nsª, nsb
Late rejection episodes ≥3 months (N, %) 4 (11%) 2 (10%) 8 (12%) ns nsª, nsb
Deceased donor (N, %) 8 (22%) 6 (29%) 23 (35%) ns nsª, nsb
HLA matching living donor (N, %) 29 (78%) 15 (71%) 42 (65%) 0.014 nsª, nsb
Delayed graft function (N, %) 8 (22%) 3 (15%) 17 (26%) ns nsª, nsb
New onset diabetes after Tx (N, %) 7 (19%) 2 (10%) 2 (3%) ns nsª, nsb
Anti-HBV antibodies (N, %) 6 (16%) 1 (5%) 5 (8%) ns nsª, nsb
Anti-HCV antibodies (N, %) 8 (22%) 3 (15%) 9 (14%) ns nsª, nsb
CMV antigenemia (N, %) 10 (27%) 16 (76%) 6 (9%) 0.001 nsª, nsb
Mean transplant time at graft biopsy (months) 41 ± 26 23 ± 20 26 ± 24 0.003 0.011ª, 0.014b
Serum creatinine (mg/dL) 2.3 ± 1.7 1.6 ± 0.5 1.9 ± 0.6 ns nsª, nsb
Proteinuria (g/24 h) at 1st year post-Tx 1.0 ± 2.1 1.7 ± 3.8 0.2 ± 0.9 0.020 nsª, nsb
IF/TA (≥ grade II Banff 05 classification) 29 (78%) 14 (67%) 17 (26%) 0.000 nsª, nsb
ACEI therapy (N, %) 29 (78%) 12 (57%) 65 (100%) 0.000 nsª, nsb
Initial immunosuppressive therapy
CsA (N, %) 34 (92%) 18 (86%) 53 (82%) ns nsª, nsb
Tacrolimus (N, %) 1 (3%) 2 (10%) 11 (17%) ns nsª, nsb
Rapamycin (N, %) 4 (11%) 2 (10%) 3 (5%) ns nsª, nsb
Azathioprine (N, %) 24 (65%) 17 (81%) 49 (75%) ns nsª, nsb
MMF (N, %) 7 (19%) 0 (0%) 12 (18%) 0.023 nsª, nsb
CTG = chronic transplant glomerulopathy; RGN = recurrent post-transplant glomerulonephritis; IF/TA = interstitial fibrosis 
and tubular atrophy; Tx = transplant; HLA = human leukocyte antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; 
CMV = cytomegalovirus; ACEI = angiotensin-converting enzyme inhibitor; CsA = cyclosporin A; MMF = mycophenolate 
mofetil. ANOVA: P+ = mean of all groups; P* = ªbetween CTG and RGN; bbetween CTG and IF/TA; ns = non-signifi-
cant. 
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0.03-0.54, P = 0.004). Factors associ-
ated with allograft loss were: a positive 
HCV serology (HR = 7.29, 95%CI = 
1.98-26.85, P = 0.003) and delayed al-
lograft dysfunction (HR = 5.32, 95%CI = 
1.36-20.82, P = 0.016). In addition, hav-
ing some degree of glomerular damage 
increased the risk of allograft loss more 
than the diagnosis of IF/TA by itself (HR 
= 4.04, 95%CI = 1.33-15.51, P = 0.015). 
In contrast, CMV antigenemia, gender, 
type of donor, the presence of early re-
jection, steroid-resistant rejection, and 
the time between transplantation and 
diagnosis were not statistically relevant 
(see Table 2).
Discussion
There is extensive evidence that 
incipient histological changes charac-
teristic of IF/TA can be visualized in the 
allograft before the transplant function 
deteriorates and the serum creatinine 
level is not the best predictor for renal 
allograft dysfunction in the early stages 
(13-16). 
This study reviewed 123 biopsy-
proven IF/TA specimens, which were 
classified as IF/TA without glomerular 
Figure 1. Graft survival of patients with chronic transplant glom-
erulopathy (CTG, dotted line), recurrent post-transplant glomer-
ulonephritis (RGN, solid line) and interstial fibrosis and tubular 
atrophy (IF/TA, dashed line). Graft survival after transplantation 
was statistically different among the groups (P = 0.004, Kaplan 
Meier-graft survival curves). 
Figure 2. Graft survival after biopsy of patients with chronic trans-
plant glomerulopathy (CTG, dotted line), recurrent post-transplant 
glomerulonephritis (RGN, solid line) and interstial fibrosis and tu-
bular atrophy (IF/TA, dashed line). Graft survival after allograft bi-
opsy was markedly reduced for patients with RGN and CTG com-
pared with IF/TA (P = 0.013, Kaplan Meier-graft survival curves).
Table 2. Co-variables that significantly predicted graft loss in multivariate analyses. 
Variables P HR 95%CI for HR
Lower Upper
Initial Cox hazard model
Use of ACEI 0.005 0.14 0.03 0.56
Use of MMF 0.046 0.14 0.02 0.97
Delayed graft function 0.020 7.94 1.39 45.31
CMV antigenemia ns 1.71 0.49 5.97
Renal acute rejection ns 1.58 0.37 6.60
Corticoid resistant rejection ns 0.33 0.05 2.18
Time of transplantation between Tx and biopsy 0.038 0.97 0.95 0.99
Gender ns 0.57 0.18 1.84
Type of donor (deceased) ns 1.18 0.29 4.70
Hepatitis C virus antibodies 0.001 14.63 2.85 74.88
Serum creatinine (mg/dL) ≤1.5 at 1st year post-Tx 0.009 0.13 0.02 0.60
Proteinuria (g/24 h) ≤0.5 at 1st year post-Tx 0.004 0.11 0.02 0.51
Presence of glomerular damage 0.046 3.90 1.02 14.87
Final Cox hazard model
Use of ACEI 0.001 0.12 0.03 0.41
Use of MMF 0.026 0.17 0.03 0.80
Delayed graft function 0.016 5.32 1.36 20.82
Hepatitis C virus antibodies 0.003 7.29 1.98 26.85
Serum creatinine (mg/dL) ≤1.5 at 1st year post-Tx 0.011 0.20 0.05 0.69
Proteinuria (g/24 h) ≤0.5 at 1st year post-Tx 0.004 0.14 0.03 0.54
Presence of glomerular damage 0.015 4.55 1.33 15.51
HR = hazard rate; ns = non-significant. For other abbreviations, see legend to Table 1.
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damage, chronic transplant glomerulopathy and recurrent 
post-transplant glomerulonephritis. The biopsies showed 
that an early presentation of proteinuria without elevation of 
serum creatinine level (in most cases with glomerular lesion) 
was present in the CTG and RGN groups in contrast to the 
IF/TA group (without glomerular lesion). As cited, the three 
post-transplant conditions can share the same features. 
This makes it difficult to establish a differential diagnosis 
between the advanced grade of IF/TA, including chronic 
transplant glomerulopathy, and the recurrent post-transplant 
glomerulonephritis that manifests as proteinuria, consider-
ing only clinical and laboratory markers. Nevertheless, in the 
present study, it was possible to show that these diseases 
have peculiar clinical and laboratory profiles.
Although we found different stages of damage in the 
biopsies, the serum creatinine level at the time of the graft 
biopsy was not significantly different among groups. In 
contrast, 24-h urinary protein excretion was significantly 
different between CTG and IF/TA, while CTG and RGN 
showed high and similar proteinuria levels. As a progression 
marker (14,15), urinary protein excretion was a predictor 
of graft function loss, with the RGN group presenting the 
worst graft survival rate. Patients with CTG had a poorer 
graft survival than those without CTG. After the diagnosis 
of transplant glomerulopathy, the patients of this group 
progressed more rapidly to end-stage renal disease than 
those whose graft biopsy revealed IF/TA without transplant 
glomerulopathy. 
Proteinuria, especially if elevated and persistent, is a 
well-defined indicator of the progressive nature of renal 
disease in native kidneys (5,16). Our results showed that 
higher levels of proteinuria after transplantation are also 
related to a poorer prognosis of the renal allograft. This 
appears to be associated with the presence of RGN. This 
finding emphasizes the need for biopsies to reveal the cause 
of proteinuria after transplantation. The impact of RGN on 
graft outcome is important and this diagnosis should be 
considered when proteinuria is present. 
In addition, we found that one of the factors associated 
with renal allograft loss in these selected groups of patients 
was the presence of anti-HCV antibodies, even though it 
was not significant in univariate analysis. This variable was 
analyzed because it is a well-known risk factor for renal graft 
loss. In our study, patients carrying anti-HCV antibodies 
had 11.7 times higher risk of graft loss than those with no 
anti-HCV antibodies. This finding agrees with recent stud-
ies suggesting that the risk of transplant glomerulopathy 
increases in patients exposed to HCV and CMV infections 
(17,18). The presence of CMV antigenemia was not statisti-
cally significant in multivariate analysis. 
Another risk factor associated with renal allograft loss 
was a delayed allograft dysfunction episode. This episode 
increased the risk of allograft loss by 4.9. This finding has 
been reported by others although it is controversial (19-22). 
Delayed graft function increases the risk of acute rejection 
by leading to an overwhelming immune response to the al-
lograft. The presence of increased immune material leads to 
increased production of fibrotic material and to a decrease 
in functioning tubules. This increases the prevalence and 
severity of IF/TA (22) and consequently becomes a risk factor 
for allograft loss, as observed in the present study. 
As cited above, the CTG and RGN groups showed lower 
allograft survival rates when compared to the IF/TA group. 
This finding is in accordance with the current literature that 
describes chronic rejection as the first cause of renal al-
lograft loss, followed by death with a functioning graft and 
immune complex-mediated glomerulonephritis (recurrent 
and de novo). Hariharan et al. (23) have demonstrated 
that glomerular disease recurrence determines a 1.9 times 
higher relative risk of graft loss after 5 years of follow-up 
compared to patients without recurrence. 
It is of note that the present study was not randomized 
or controlled and had limitations associated with its retro-
spective design. Immunofluorescence was not available 
for 29% of the patients in the RGN group because dur-
ing the period of case inclusion in this study renal biopsy 
specimens were not routinely assessed by this technique 
in our service. Therefore, it is necessary to say that, with-
out immunofluorescence analysis, eventual cases of IgA 
nephropathy could have been missed. Nevertheless, within 
the context of this study, it is not probable that the glomeru-
lonephritis classified as recurrent (as there was a diagnosis 
of glomerulonephritis in native kidneys) could correspond to 
another post-transplant glomerulonephritis. Also, electron 
microscopy was not available for most cases. 
The authors are aware that the absence of immunoper-
oxidase studies for the detection of C4d deposition is an 
important limitation, and this approach will be indispensable 
in further studies about these particular issues. It is of note 
that Sis et al. (24) reported that 70% of 53 CTG biopsies 
had anti-HLA, 36% C4d staining, 91% capillaritis, and 35% 
glomerulitis. However, only 53% of CTG with alloantibody 
showed C4d, suggesting that C4d staining has low sensitivity 
for chronic antibody-mediated rejection, but CTG with no 
endothelial stress showed good survival. 
In the current study, the presence of glomerular damage 
was a risk factor for renal allograft loss independently of the 
presence of IF/TA. This finding agrees with recently pub-
lished studies (25-29). Wavamunno et al. (30) showed that 
endothelial and subendothelial ultrastructural abnormalities 
in glomerular and peritubular capillaries are sensitive early 
markers of CTG. They are associated with C4d deposition 
subsequently detected by light microscopy.
Our results show that the use of MMF and renin-angio-
tensin system (RAS) blockade provide some protection of 
the renal allograft. MMF could be responsible for this effect 
because its immunosuppressive activity (31) also inhibits 
the expression of adhesion molecules on endothelial cells 
and the proliferation of arterial smooth cells (31-34), thereby 
retarding the infiltration of inflammatory cells (33,34), and 
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possibly delaying the onset/progression of IF/TA (32,35). 
Additionally, it is well-known that RAS blockade delays the 
progression of glomerulosclerosis and interstitial fibrosis in 
proteinuric diseases (36,37). The investigators have shown 
that RAS blockade is efficient in reducing proteinuria and 
delaying the rate of decline of renal function in patients 
with post-transplant glomerulonephritis. On the basis of 
these considerations, an early diagnosis of proteinuria 
and its cause have prognostic and relevant therapeutic 
consequences (38,39).
Finally, the treatment and prevention of IF/TA and renal 
allograft rejection remain a challenge (32,40). In fact, the 
numerous unanswered questions in this area motivated the 
present study. We searched for morphological and functional 
markers that could distinguish renal lesions that contribute 
to loss of the renal graft, particularly the contribution of the 
glomerular compartment. Considering the limitations of 
the study design and the sample size, it was apparent that 
the functional parameters evaluated were not adequate to 
permit a differential diagnosis of the three histological groups 
in this context, but they could contribute to the suspicion of 
the type of graft involvement and to the early indication of 
a renal biopsy. We emphasize that more attention should 
be devoted to the identification of clinical and laboratory 
risk factors for graft loss. In addition, different histological 
diagnoses of graft loss were demonstrated in the present 
study. Certainly, the differentiation of chronic immunologic 
rejection from other causes of chronic allograft dysfunc-
tion is especially important in renal biopsies, because the 
treatment of such conditions is completely different. Chronic 
transplant glomerulopathy, as well as post-transplant 
glomerulonephritis, are well known causes of loss of renal 
allograft that deserve an early diagnosis and intervention. 
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